Puma Biotechnology (PBYI) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $10.52, +3.14% vs the prior close of $10.20.
- Volume 377.40K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PBYI jumps 3.1% to $10.52, a 52-week high. Closed at $10.52, +3.14% vs the prior close of $10.20. Day range $10.28–$10.72, opened at $10.30.
PBYI daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — PBYI jumps 3.1% to $10.52, a 52-week high
- Closed at $10.52, +3.14% vs the prior close of $10.20. Day range $10.28–$10.72, opened at $10.30.
- Volume was 377.40K shares, 1.2x its 50-day average of 323.98K.
- Price is +11.7% vs its 50-day average ($9.42) and +37.3% vs its 200-day average ($7.66).
- 52-week range $4.58–$10.72; today's close sits at 97% of that range, 1.9% below the 52-week high.
Oct 14, 2026 — PBYI rises 0.8% to $10.20
- Closed at $10.20, +0.79% vs the prior close of $10.12. Day range $10.03–$10.43, opened at $10.09.
- Volume was 327.00K shares, 1.0x its 50-day average of 322.83K.
- Price is +8.9% vs its 50-day average ($9.37) and +33.5% vs its 200-day average ($7.64).
- 52-week range $4.58–$10.50; today's close sits at 95% of that range, 2.9% below the 52-week high.
Oct 13, 2026 — PBYI dips 1.7% to $10.12
- Closed at $10.12, -1.65% vs the prior close of $10.29. Day range $10.10–$10.40, opened at $10.27.
- Volume was 295.60K shares, 0.9x its 50-day average of 323.69K.
- Price is +8.6% vs its 50-day average ($9.32) and +32.8% vs its 200-day average ($7.62).
- 52-week range $4.58–$10.50; today's close sits at 94% of that range, 3.6% below the 52-week high.
Oct 12, 2026 — PBYI ends flat (+0.0%) to $10.29
- Closed at $10.29, +0.00% vs the prior close of $10.29. Day range $10.27–$10.50, opened at $10.32.
- Volume was 284.80K shares, 0.9x its 50-day average of 323.29K.
- Price is +11.0% vs its 50-day average ($9.27) and +35.4% vs its 200-day average ($7.60).
- 52-week range $4.58–$10.50; today's close sits at 96% of that range, 2.0% below the 52-week high.
Oct 9, 2026 — PBYI jumps 3.2% to $10.29, a 52-week high, 3 up days in a row
- Closed at $10.29, +3.21% vs the prior close of $9.97. Day range $9.85–$10.36, opened at $9.96.
- Volume was 303.10K shares, 0.9x its 50-day average of 322.43K.
- Price is +11.5% vs its 50-day average ($9.23) and +35.8% vs its 200-day average ($7.58).
- 52-week range $4.58–$10.36; today's close sits at 99% of that range, 0.7% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — PBYI rises 1.6% to $9.97, a 52-week high
- Closed at $9.97, +1.63% vs the prior close of $9.81. Day range $9.45–$10.00, opened at $9.75.
- Volume was 356.50K shares, 1.1x its 50-day average of 319.31K.
- Price is +8.6% vs its 50-day average ($9.18) and +32.0% vs its 200-day average ($7.55).
- 52-week range $4.58–$10.10; today's close sits at 98% of that range, 1.3% below the 52-week high.
Oct 7, 2026 — PBYI jumps 3.3% to $9.81
- Closed at $9.81, +3.26% vs the prior close of $9.50. Day range $9.41–$9.96, opened at $9.45.
- Volume was 375.30K shares, 1.2x its 50-day average of 318.01K.
- Price is +7.4% vs its 50-day average ($9.13) and +30.2% vs its 200-day average ($7.53).
- 52-week range $4.58–$10.10; today's close sits at 95% of that range, 2.9% below the 52-week high.
Oct 6, 2026 — PBYI dips 1.8% to $9.50
- Closed at $9.50, -1.76% vs the prior close of $9.67. Day range $9.43–$9.80, opened at $9.72.
- Volume was 322.70K shares, 1.0x its 50-day average of 314.43K.
- Price is +4.4% vs its 50-day average ($9.10) and +26.5% vs its 200-day average ($7.51).
- 52-week range $4.58–$10.10; today's close sits at 89% of that range, 5.9% below the 52-week high.
Oct 5, 2026 — PBYI rises 1.7% to $9.67
- Closed at $9.67, +1.68% vs the prior close of $9.51. Day range $9.33–$9.78, opened at $9.45.
- Volume was 297.60K shares, 1.0x its 50-day average of 312.60K.
- Price is +6.6% vs its 50-day average ($9.07) and +29.1% vs its 200-day average ($7.49).
- 52-week range $4.58–$10.10; today's close sits at 92% of that range, 4.3% below the 52-week high.
Oct 2, 2026 — PBYI slides 3.4% to $9.51
- Closed at $9.51, -3.35% vs the prior close of $9.84. Day range $9.50–$10.00, opened at $9.94.
- Volume was 454.70K shares, 1.5x its 50-day average of 308.10K.
- Price is +5.3% vs its 50-day average ($9.03) and +27.3% vs its 200-day average ($7.47).
- 52-week range $4.58–$10.10; today's close sits at 89% of that range, 5.8% below the 52-week high.
PBYI latest news & SEC filings
Every SEC filing by or about PBYI in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wilson Troy Edward sold 5,000 shares at $9.10 (≈$45.50K) on Sep 14, 2026; now holds 54,750
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cesano Alessandra converted options/RSUs into 50,000 shares at $2.93 (≈$146.50K) on Sep 14, 2026; now holds 118,850
- Cesano Alessandra sold 62,150 shares at $9.12 (≈$566.99K) on Sep 14, 2026; now holds 56,700
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $56.50M (prior year $52.44M) (+7.8% vs Jun 30, 2025)
- Net income: $8.19M (prior year $5.86M) (+39.9% vs Jun 30, 2025)
- Diluted EPS: $0.16 (prior year $0.12) (+33.3% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Auerbach Alan H sold 44,058 shares at $8.26 (≈$363.92K) on Jul 6, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hunt Douglas M sold 8,460 shares at $8.26 (≈$69.88K) on Jul 6, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade PBYI
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.95% (largest 5.8%).
- Liquidity: about 344.46K shares (≈$3.62M) trade per day on average.
- 52-week position: $10.52 vs a range of $4.58–$10.72 (97% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 17 sales; latest: Troy Edward Wilson sold 5,000 shares on Sep 14, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 16, 2026.
- Share count: 51.62M shares outstanding (Aug 3, 2026), +2.5% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PBYI market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 10.30 | 10.72 | 10.28 | 10.52 | 377.40K |
| Oct 14, 2026 | 10.09 | 10.43 | 10.03 | 10.20 | 327.00K |
| Oct 13, 2026 | 10.27 | 10.40 | 10.10 | 10.12 | 295.60K |
| Oct 12, 2026 | 10.32 | 10.50 | 10.27 | 10.29 | 284.80K |
| Oct 9, 2026 | 9.96 | 10.36 | 9.85 | 10.29 | 303.10K |
| Oct 8, 2026 | 9.75 | 10.00 | 9.45 | 9.97 | 356.50K |
| Oct 7, 2026 | 9.45 | 9.96 | 9.41 | 9.81 | 375.30K |
| Oct 6, 2026 | 9.72 | 9.80 | 9.43 | 9.50 | 322.70K |
| Oct 5, 2026 | 9.45 | 9.78 | 9.33 | 9.67 | 297.60K |
| Oct 2, 2026 | 9.94 | 10.00 | 9.50 | 9.51 | 454.70K |
| Oct 1, 2026 | 9.84 | 10.08 | 9.77 | 9.84 | 518.40K |
| Sep 30, 2026 | 9.85 | 10.10 | 9.74 | 9.93 | 399.00K |
| Sep 29, 2026 | 9.77 | 9.90 | 9.68 | 9.78 | 220.60K |
| Sep 28, 2026 | 9.77 | 9.89 | 9.54 | 9.82 | 245.90K |
| Sep 25, 2026 | 9.90 | 9.90 | 9.65 | 9.77 | 262.00K |
| Sep 24, 2026 | 9.25 | 9.87 | 9.02 | 9.82 | 467.40K |
| Sep 23, 2026 | 9.82 | 9.90 | 9.08 | 9.28 | 475.90K |
| Sep 22, 2026 | 9.65 | 9.98 | 9.57 | 9.82 | 360.70K |
| Sep 21, 2026 | 9.66 | 9.75 | 9.51 | 9.59 | 217.60K |
| Sep 18, 2026 | 9.52 | 9.66 | 9.44 | 9.60 | 327.10K |
About Puma Biotechnology
Puma Biotechnology (PBYI) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LOS ANGELES, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1401667.
PBYI board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Alan H Auerbach | President and CEO | Jul 8, 2026 |
| Alessandra Cesano | Director | Sep 16, 2026 |
| Allison Dorval | Director | Jun 15, 2026 |
| Michael Patrick Miller | Director | Jun 15, 2026 |
| Jay M Moyes | Director | Jun 15, 2026 |
| Adrian Senderowicz | Director | Jun 15, 2026 |
| Brian M Stuglik | Director | Jun 15, 2026 |
| Troy Edward Wilson | Director | Sep 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Alan H Auerbach | President and CEO | Jul 8, 2026 |
| Douglas M Hunt | See Remarks | Jul 8, 2026 |
| Maximo F Nougues | Chief Financial Officer | Jul 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | Troy Edward Wilson | Sale | 5,000 | $9.10 |
| Sep 14, 2026 | Alessandra Cesano | Sale | 62,150 | $9.12 |
| Jul 6, 2026 | Maximo F Nougues | Sale | 9,386 | $8.26 |
| Jul 6, 2026 | Douglas M Hunt | Sale | 8,460 | $8.26 |
| Jul 6, 2026 | Alan H Auerbach | Sale | 44,058 | $8.26 |
| Jun 12, 2026 | Troy Edward Wilson | Sale | 10,800 | $7.20 |
| Jun 12, 2026 | Brian M Stuglik | Sale | 8,100 | $7.20 |
| Jun 12, 2026 | Jay M Moyes | Sale | 22,000 | $7.22 |
| Jun 12, 2026 | Adrian Senderowicz | Sale | 27,000 | $7.20 |
| Jun 12, 2026 | Allison Dorval | Sale | 11,610 | $7.20 |
| Jan 7, 2026 | Maximo F Nougues | Sale | 6,405 | $5.88 |
| Jan 7, 2026 | Alan H Auerbach | Sale | 18,012 | $5.88 |
| Jan 7, 2026 | Douglas M Hunt | Sale | 5,014 | $5.88 |
| Jan 6, 2026 | Maximo F Nougues | Sale | 4,540 | $5.84 |
| Jan 6, 2026 | Alan H Auerbach | Sale | 16,938 | $5.84 |
PBYI financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $228.37M | $31.11M | 0.61 | $41.80M |
| Dec 31, 2024 | $230.47M | $30.28M | 0.62 | $38.92M |
| Dec 31, 2023 | $235.64M | $21.59M | 0.45 | $27.01M |
| Dec 31, 2022 | $228.03M | $2.00K | 0.00 | $-15.83M |
| Dec 31, 2021 | $253.16M | $-29.13M | -0.72 | $20.65M |
Latest balance sheet: total assets $192.74M, total liabilities $54.19M, cash $36.54M (as of Jun 30, 2026).
PBYI earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $8.12 |
| May 7, 2026 | 8-K Item 2.02 (results) | $7.26 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $7.60 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $4.90 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $3.29 |
| May 8, 2025 | 8-K Item 2.02 (results) | $3.07 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $2.99 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $3.03 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on PBYI
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.